"I am glad that taking part in a trial might help others on their own cancer journey.”
A trial looking at treatment for cytomegalovirus after stem cell or bone marrow transplant (CMV IMPACT)
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
This trial is looking at a new treatment called adoptive cellular therapy (ACT) to treat cytomegalovirus (CMV) after a stem cell or bone marrow transplant.
Following a stem cell or bone marrow transplant the system in the body that fights infection (immune system) may not work properly for several months. During this time serious infections may occur that a healthy body is able to control. The most common infection following a transplant is cytomegalovirus.
Cytomegalovirus (CMV) is common and can cause several types of infections. Most people will have had a CMV infection by the time they are adults. It isn’t generally serious. But the virus can remain inactive in the body for many years and cause recurrent infections. This usually only becomes a problem in people who have a very weakened immune systems. For example, it can cause serious chest infections after a stem cell or bone marrow transplant.
If CMV becomes active again following a transplant doctors usually treat it with drugs. Researchers have developed a new way of treating CMV following a transplant. It is called adoptive cellular therapy – ACT. ACT is a way of boosting the immune cells that fight CMV infection.
There are 2 main ways to boost the immune cells and the researchers want to compare them to see which the best is.
The aims of this trial are to find out
- If ACT can help boost the immune system against CMV following a stem cell or bone marrow transplant
- Which is the best way to boost the immune cells for ACT
Who can enter
You can enter this trial if you
- Are going to have a stem cell or bone marrow transplant and your brother or sister is the donor
- Are CMV positive
- Have alemtuzumab before your transfusion
- Have satisfactory blood test results
- At least 18 years old
You cannot enter this trial if you
- Are HIV positive
- Have a medical condition that could affect you taking part in this trial
- Are pregnant or breastfeeding
The researchers would also like to ask your brother or sister to take part in this trial in order to donate cells for ACT. To take part they must be
- Well enough to be a donor
- CMV positive
- At least 16 years old
They cannot enter the trial if they
- Have tested positive for syphilis, HIV, hepatitis B or C
- Are pregnant or breastfeeding
This is a phase 3 trial. This trial will recruit 95 people who are to have a transplant. The trial will also recruit the brother or sister who is the donor.
It is a randomised trial. There are 2 groups. People in group 1 will have adoptive cellular therapy - ACT. People in group 2 will have standard treatment only for CMV. Three out of every five people will be put into group 1. So you have a 3 out of 5 chance of having the experimental treatment in this trial.
ACT is like a second transplant with a certain type of cell. The researchers select the immune cells of your donor with the ability to fight CMV infection. You then have these immune cells that fight CMV through a drip into a vein, like a transfusion.
Everyone will have a physical examination and blood tests 25 days after their transplant.
If you are in the group having ACT, you have it 2 days later.
If you agree to take part in this trial the researchers will ask your permission to store some of the samples they take. The researchers may use these in the future for further research. You can choose not to have your samples stored and still take part in the trial.
After your transplant you see the doctor for a physical examination and blood tests
- Every week for 4 weeks
- Every month for 7 months
If you are not in hospital, you attend the outpatient’s department to see the doctor.
If you take part in the trial there are no additional visits as these will be the same as the routine visits after your transplant.
How to join a clinical trial
Dr Karl Peggs
Cell Medica Limited
Experimental Cancer Medicine Centre (ECMC)
The Wellcome Trust